Neutrophil-activating Peptide-2 and Melanoma Growth-stimulatory Activity Are Functional as Monomers for Neutrophil Activation*

(Received for publication, May 9, 1996, and in revised form, October 9, 1996)

Krishna Rajarathnam Dagger §, Cyril M. Kay Dagger , Beatrice Dewald , Marlene Wolf , Marco Baggiolini , Ian Clark-Lewis par and Brian D. Sykes Dagger

From the Dagger  Protein Engineering Network of Centres of Excellence (PENCE) and the Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2S2, Canada, the  Theodor-Kocher Institute, University of Bern, P.O. Box 99, CH-3000 Bern, Switzerland, and par  PENCE, the Biomedical Research Centre and the Department of Biochemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Neutrophil-activating peptide-2 (NAP-2) and melanoma growth-stimulatory activity (MGSA) are members of the chemokine family of inflammatory proteins. The structures of NAP-2, determined by x-ray crystallography, and MGSA, elucidated by NMR spectroscopy, revealed a tetramer and dimer, respectively. In order to address the relevance of multimeric species to their activities on neutrophils, analogs of NAP-2 and MGSA were synthesized in which the backbone amide proton of Leu-22 in NAP-2, and Val-26 in MGSA, was substituted with the bulky methyl group (NH right-arrow NCH3). These analogs were shown to be monomeric by sedimentation equilibrium ultracentrifugation studies and were similar to the corresponding native protein in assays for neutrophil elastase release and Ca2+ mobilization from IL-8R1 and IL-8R2 transformed cells. Sedimentation equilibrium studies of the native NAP-2 and MGSA were also carried out to address the association behavior. For NAP-2, there was no evidence for the tetramer, but an equilibrium between monomers and dimers and the dissociation constant was calculated to be 50-100 µM. Similarly, MGSA showed a monomer-dimer equilibrium with a Kd of ~5 µM. The data from the monomeric analogs and also the calculation of dissociation constants indicate that NAP-2 and MGSA have a tendency to associate above the concentrations required for maximal activity or for receptor activation, but at functional concentrations they are predominantly monomers.


INTRODUCTION

Recruitment and accumulation of circulating leukocytes at the site of inflammation are mediated in part by a family of small molecular weight proteins called chemokines (1-3). They have four conserved cysteines and are called either CXC or CC chemokines, depending on whether the first two cysteines are separated by one amino acid (CXC) or are adjacent (CC). Functionally, the CXC chemokines predominantly attract neutrophils, whereas CC chemokines attract monocytes, lymphocytes, and eosinophils.

Three well studied proteins of the CXC chemokine family are interleukin-8 (IL-8)1, melanoma growth-stimulatory activity (MGSA), and neutrophil-activating peptide-2 (NAP-2). The structure of IL-8 has been solved by both NMR and x-ray methods, and both approaches indicated it to be a dimer (4, 5). NMR studies of MGSA (6, 7) and x-ray studies of a variant of NAP-2 (M6L) (8) indicated them to be a dimer and tetramer, respectively. The tertiary and quaternary structures of IL-8 and MGSA are similar, and NAP-2 adopts a similar structure while showing an additional level of complexity by forming a tetramer. The tertiary structure consists of a series of turns and loops in the N-terminal region followed by three beta -strands and a C-terminal alpha -helix. In the dimeric structure, the three beta -strands from each monomer form a six-stranded beta -sheet with the helices transversing the beta -sheet. On the basis of the dimeric structure of IL-8, it was previously thought that dimerization is essential for function. However, we subsequently demonstrated that an analog in which Leu-25 was substituted with N-methylleucine (L25NMe) was monomeric and had similar functional properties as the native IL-8 (19). The structure of this synthetic IL-8 monomer was solved by 1H NMR spectroscopy and was shown to be largely similar to that of the monomeric unit in the NMR and x-ray structures of the native dimer (16). Taken together, these observations suggested that dimerization of IL-8 is essential neither for structural integrity nor for functional activation.

Two receptors (IL-8R1 and IL-8R2) that bind CXC chemokines have been identified and characterized in neutrophils, and they belong to the superfamily of seven transmembrane domain-containing proteins that bind to G-proteins. IL-8R2 binds IL-8, MGSA, and NAP-2 with equal affinity. In contrast, IL-8R1 binds only IL-8 with high affinity, but it does bind MGSA and NAP-2 with low affinity (9-11). The N-terminal residues Glu-4, Leu-5, and Arg-62 (the "ELR" motif) (Fig. 1) are conserved and are absolutely essential for receptor binding in MGSA, NAP-2, and IL-8 (12-15). Differential binding to the two receptors has been attributed to a region of about 10 residues immediately preceding the first beta -strand, and these residues are similarly located away from the interface (17, 18). Mutation of charged residues at the dimer interface in IL-8 had no affect on activity (18). Thus, functional data indicate that the residues at the dimer interface are not directly involved in receptor binding.


Fig. 1. The alignment of the amino acid sequences of IL-8, MGSA, and NAP-2. The residues highlighted in the different proteins constitute the dimer interface.
[View Larger Version of this Image (10K GIF file)]


In order to address the relevance of higher order states observed in structures of NAP-2 and MGSA, monomeric analogs of NAP-2 and MGSA were synthesized using a similar strategy employed in the synthesis of the monomeric IL-8 (19). For MGSA, Val-26 was substituted with N-methylvaline, and for NAP-2, Leu-22 was substituted with N-methylleucine. In addition to disrupting hydrogen bonding across the dimer interface, the modification also introduces a bulky methyl group, which prevents monomers from coming close to each other. We show here that the monomeric analogs of NAP-2 and MGSA have an activity similar to that of the corresponding native proteins for neutrophil elastase release and induce a similar rise in free Ca2+ in Jurkat cells transfected with either IL8-R1 or IL8-R2, indicating that dimerization is not essential for receptor binding and functional activation. Furthermore, calculations of Kd by sedimentation equilibrium for both NAP-2 and MGSA indicate that they are predominantly monomeric at functional nanomolar concentrations.


EXPERIMENTAL PROCEDURES

Protein Synthesis and Biological Assay

All proteins were chemically synthesized, purified, and characterized as discussed in detail previously (20). The monomeric MGSA and NAP-2 were synthesized using the same strategy as that used for IL-8 (19). Val-26 in MGSA and Leu-22 in NAP-2, the residues corresponding to Leu-25 in IL-8, were substituted with N-methylleucine and N-methylvaline, respectively. The synthesis was performed using t-butoxycarbonyl chemistry, and longer reaction times were required for the addition of the protected amino acid following the N-methyl-amino acid (NH2-terminal amino acid), apparently due to slow reaction kinetics. The analogs were purified by HPLC and characterized by ion spray mass spectroscopy (SCIEX AP III) as described previously. MGSA was synthesized without the last Asn residue, and this analog was shown to have the same activity as the full-length protein. Elastase release from freshly purified neutrophils (21) and Ca2+ induction from Jurkat cells transfected with IL-8R1 and IL-8R2 receptors were performed as described previously (22).

Ultracentrifugation Studies

Sedimentation equilibrium studies were performed on a Beckman Spinco model E analytical ultracentrifuge using Raleigh interference optics. The samples were extensively dialyzed for a period of 48 h against the appropriate buffer. 100 µl of the samples was loaded into 12-mm double-sector, charcoal-filled Epson cells equipped with sapphire windows. Sedimentation equilibrium runs of all of the proteins were carried out at a concentration of ~1 mg/ml in 100 mM NaCl, 50 mM sodium phosphate, pH 7.0. Runs were carried out at rotor speeds between 24,000 and 32,000 rpm, depending on the sample, for a period of 48 h, and photographs were taken when fringes could be resolved across the boundary region between the protein solution and the solvent. For both native NAP-2 and MGSA, data were collected using at least two different rotor speeds, two different pH values, and/or two different starting concentrations.

The average molecular weights (Mav) from sedimentation equilibrium runs were calculated using the equation,
M<SUB><UP>av</UP></SUB>=<FR><NU>2RT  d(<UP>ln</UP> C)</NU><DE>(1−<A><AC>v</AC><AC>¯</AC></A>&rgr;)&ohgr;<SUP>2</SUP> d(r<SUP>2</SUP>)</DE></FR> (Eq. 1)
where R is the universal gas constant and is equal to 8.314 × 107 erg/mol/K; T is the temperature in K; rho  is the solvent density, which was calculated to be 1.005; omega  is the angular velocity (rpm × 2pi /60) in radians/s; vbar , the partial specific volume of the protein, was calculated from the amino acid composition (23); C is concentration in units of mg/ml, which is calculated from vertical fringe displacement. An average refractive increment of 4.1 fringes/mg/ml was used in the calculation of the concentrations (24), and d(ln C)/dr2 is the slope from the plots in Fig. 2.


Fig. 2. The average molecular weight determination by sedimentation equilibrium of MGSA (open circle ) and the V25NMe MGSA analog (bullet ) (A) and native NAP-2 (open circle ) and the L22NMe NAP-2 analog (bullet ) (B). Plots of ln C versus r2omega 2 are shown, where C is the concentration in fringe displacement units, r is the distance from the axis of rotation, and omega  is the angular velocity. All of the samples were in 50 mM sodium phosphate, 100 mM sodium chloride at pH 7.0. Molecular weights were calculated from the slopes of the plot (Equation 1). The native MGSA was run at an initial concentration of 1.0 mg/ml at 26,000 rpm; the V25NMe MGSA at an initial concentration of 2.1 mg/ml at 26,000 rpm; native NAP-2 at an initial concentration of 1.0 mg/ml at 26,000 rpm; and the L22NMe NAP-2 at an initial concentration of 1.4 mg/ml at 32,000 rpm. For clarity of presentation, a constant value of 1 and 2 were added to ln C and r2omega 2, respectively, for MGSA, and a value of 17.5 was added to r2omega 2 for NAP-2.
[View Larger Version of this Image (15K GIF file)]


The dissociation constant for the monomer-dimer equilibrium was calculated from the equation (25),
C<SUB>r</SUB>=C<SUB>o</SUB><UP>exp</UP>[HM&dgr;]+<UP>C</UP><SUB>o</SUB><SUP>2</SUP>K<SUB>a</SUB><UP>exp</UP>[2HM&dgr;]+E (Eq. 2)
where delta  is (r2 - ro2) and Cr and Co are the concentrations as measured by the scattering method at positions r and ro, respectively. H = (1 - vbar rho ) × omega 2/2RT, M is the molecular weight of the monomer, Ka is the association constant for the monomer-dimer equilibrium, and E is the offset. The calculated equilibrium constant (Ka) is in units of mg/ml and is converted into molar units (KA) by multiplying with the molecular weight of the monomer (KA Ka × M/2).

The data were fitted using the curve-fitting routine in Table Curve (Jandel Scientific). The estimated Kd is given at a 95% confidence interval. For the monomeric proteins, the data could be fitted to a single species, and for the native proteins, the data could be fitted to a simple monomer-dimer equilibrium. There was no need to fit the data to a more complex monomer-dimer-tetramer equilibrium, and when this was tried there was no significant improvement of the residuals, indicating that the monomer-dimer equilibrium adequately fits the data.


RESULTS AND DISCUSSION

Characterization of Monomeric and Native MGSA

Sedimentation equilibrium ultracentrifugation data of V26NMe MGSA (Fig. 2A) indicated that this analog is a monomer, since the calculated molecular weight (7,880) (Equation 1) was very similar to the experimental molecular weight (7,640). The data could be fitted to a single species with no evidence of a dimer form. The Mav of native MGSA at pH 7.0 was calculated from Equation 1 to be 13.7 kDa (monomer molecular weight, 7,865) with a mass distribution between 11 and 15 kDa, indicating that it was in equilibrium between monomers and dimers (Fig. 2A). The data could be fitted to a monomer-dimer equilibrium with a dissociation constant (Kd) of 4 ± 3 × 10-6 M. The Kd at pH 5.0 was calculated to be 4.3 ± 1.4 × 10-5 M and indicated a weaker dimer interface at pH 5.0 than at pH 7.0. Consistent with these results, NMR at pH 5.5 (7) and at pH 5.1 (6) indicated that the last four residues are unstructured. The dependence of dimer association as a function of pH indicates that electrostatic interactions play a role in stabilizing the dimer structure.

Characterization of Monomeric and Native NAP-2

Ultracentrifugation data of L22NMe NAP-2 (Fig. 2B) indicated that this analog is a monomer (calculated molecular weight, 7,646; experimental molecular weight, 7,775) with no evidence for dimeric species. The average molecular mass of native NAP-2 at pH 7.0 (Fig. 2B) was calculated to be 11.6 ± 0.4 kDa (monomer molecular weight, 7,632), with a mass distribution from 10 to 14 kDa, indicating that it exists in an equilibrium between monomers and dimers. The data could be fitted adequately to a monomer-dimer equilibrium with a Kd value of 5.3 ± 2.0 × 10-5 M (Fig. 3). Unlike the case for MGSA, there was no appreciable difference in the Kd values between pH 5.0 and 7.0 (~100 and ~50 µM, respectively).


Fig. 3. Calculation of dissociation constant by sedimentation equilibrium of native NAP-2 at 100 mM NaCl, 50 mM phosphate, pH 7.0. The concentrations calculated in fringe displacement units (in mg/ml) are plotted versus r2. The dissociation constants were calculated from curve fitting the data using Equation 2. Residuals of the corresponding least square fit are random, indicating the goodness of the fit.
[View Larger Version of this Image (16K GIF file)]


These values indicate a relatively weak dimer interface compared with MGSA and IL-8. Lack of a pH effect is consistent with the NMR studies of NAP-2, which showed no differences in the Kd value for pH values between 5 and 7 (26). At 250 mM NaCl and pH 7.0, the authors calculated a dissociation constant for the monomer-dimer equilibrium as ~300 µM and for a dimer-tetramer equilibrium as ~900 µM (Table I). However, from chemical cross-linking studies, a dissociation constant of ~0.3 µM was reported for NAP-2 (27). Ultracentrifugation data are largely consistent with the NMR studies, and the ~6-fold difference is within the experimental error of the two techniques. It is likely that tetramers were not detected at the concentrations used in the sedimentation equilibrium experiment due to the large Kd value for the dimer-tetramer equilibrium. Overall, data from this study and those reported by NMR studies (26) are inconsistent with the low Kd values measured by cross-linking studies.

Table I.

Dissociation constants of NAP-2, MGSA, and IL-8

Dissociation constants were measured by sedimentation equilibrium ultracentrifugation unless otherwise indicated.
Chemokine Dissociation constant Experimental conditions Reference

m
NAP-2 5.3 (± 2.0)  × 10-5 50 mM sodium phosphate, 100 mM NaCl,   pH 7.0, 20 °C This study
10.2 (± 3.6)  × 10-5 50 mM sodium phosphate, 100 mM NaCl,   pH 5.0, 20 °C This study
Kd1 = ~3  × 10-4 250 mM NaCl, pH 7.0, 30 °C 26b
Kd2 = ~9  × 10-4
3.2 (± 0.7)  × 10-7 Phosphate-buffered saline, pH 7.4, 20 °C 27c
MGSA 4 (± 3)  × 10-6 50 mM sodium phosphate, 100 mM NaCl,   pH 7.0, 20 °C This study
4.3 (± 1.4)  × 10-5 50 mM sodium phosphate, 100 mM NaCl,   pH 5.0, 20 °C This study
IL-8 21 (± 10)  × 10-6 Phosphate-buffered saline, pH 7.4, 8 °C 34
14 (± 4)  × 10-6 20 mM sodium phosphate, 150 mM NaCl,   pH 7.4, 25 °C 33
18 (± 6)  × 10-6 20 mM sodium phosphate, 150 mM NaCl,   pH 7.4, 37 °C 33d

b  Dissociation constants were measured by NMR. Kd1 stands for monomer-dimer equilibrium, and Kd2 stands for dimer-tetramer equilibrium.
c  Dissociation constant was measured by chemical cross-linking.
d  Dissociation constant was measured by microcalorimetry.

X-ray studies of a NAP-2 variant, having the substitution Met-6 to Leu (M6L), showed the structure to be a tetramer (8). In addition to having a dimer interface like that for IL-8 (designated as A/B interface), the second interface involves residues in the N-terminal region (designated as A/C interface). In solution structures of macrophage inflammatory protein-1beta (28) and RANTES (29, 30), which are CC chemokines, N-terminal residues constitute the dimer interface. The crystal structure of platelet factor-4, a CXC chemokine, showed it to be a tetramer, and it has two dimer interfaces similar to NAP-2, an A/B interface like IL-8 and an A/C interface like RANTES (31, 32). By necessity, the crystals of NAP-2 were grown at high concentrations of the protein (17 mg/ml in 100 mM sodium acetate, 200 mM ammonium acetate, pH 4.6), and this could be the reason for the formation of the tetramer. It has been suggested by the authors that the mutation M6L may have favored interaction at the A/C interface compared with the native NAP-2, since platelet factor-4 has a Leu at the corresponding position. Since L22NMe NAP-2 is a monomer, the sedimentation equilibrium data suggest that the A/B interface is stronger than the A/C interface for NAP-2.

Structure-Function

Neutrophil elastase release activity of native MGSA and NAP-2 and the monomeric L22NMe MGSA and V26NMe NAP-2 analogs are shown in Fig. 4. The data indicate that the activities of the monomeric analogs are indistinguishable from those of the native proteins. Neutrophils have two receptors that bind ELR motif-containing chemokines, and both receptors elicit chemotaxis exocytosis and a rise in Ca2+ level response. It has been shown that IL-8, NAP-2, and MGSA elicit the same transient induction of Ca2+ from Jurkat cells transfected with IL-8R2, whereas up to 100 nM, only IL-8 elicits Ca2+ release response from cells transfected with IL-8R1 (22). Similar experiments were performed with the monomeric analogs (Fig. 5). The data clearly indicate that both the monomeric analogs elicit similar functional response as the native protein. The relative distribution of monomers and dimers for different total concentrations of NAP-2 calculated from the Kd at pH 7 is shown in Fig. 6. It is observed that at functional concentrations (0.1-10 nM), NAP-2 exists predominantly as a monomer, and at concentrations used for structural determination (~1 mM) it exists predominantly as a dimer. The distribution profile for MGSA, calculated for a Kd of 4 µM, shows a similar trend and indicates that it is predominantly monomeric at functional concentrations. The Kd for IL-8 has been determined by sedimentation equilibrium and microcalorimetry studies as 10-30 µM (33, 34) (Table I), which indicates that IL-8 also exists as a monomer at physiological concentrations (35, 36). The data from this study for MGSA and NAP-2 and previous studies for IL-8 provide experimental evidence that these chemokines have a strong propensity to associate at high concentrations but bind as monomers to the neutrophil receptors.


Fig. 4. Neutrophil elastase release activity of the MGSA (bullet ) and the monomeric V26NMe MGSA analog (open circle ) (A) and NAP-2 (bullet ) and the monomeric L22NMe NAP-2 analog (open circle ) (B). Data are representative of three assays using different neutrophil preparations
[View Larger Version of this Image (13K GIF file)]



Fig. 5. The monomeric analogs of MGSA and NAP2 activate IL-8R2 but not IL-8R1. Changes in intracellular Ca2+ were monitored in Jurkat cells that express either IL-8R1 (JIL8R1) or IL-8R2 (JIL8R2). The cells were preloaded with Fura-2, a Ca2+-sensitive fluorophor, and at the point indicated by the arrows, a 100 nM concentration of IL-8 (A), NAP-2 (B), monomeric L22NMe NAP-2 analog (C), MGSA (D), or monomeric V26NMe MGSA analog (E) was added. Data are representative of one of two similar experiments.
[View Larger Version of this Image (9K GIF file)]



Fig. 6. Mole fraction of the monomer (open circle ) and dimer species (bullet ) as a function of NAP-2 concentration. The relative amounts of the monomer and dimer were calculated using a Kd of 102 µM calculated from sedimentation equilibrium studies at pH 7.
[View Larger Version of this Image (12K GIF file)]


Implications for Receptor Binding

Various models for interaction between chemokines and their receptors have been discussed (19, 37). The data presented here are consistent with a model in which a monomeric chemokine ligand binds to a monomeric receptor. Several lines of evidence indicate that the active species is also the monomer for some of the CC chemokines. At high concentrations, I-309 and monocyte chemoattractant protein-3 exist as monomers with no evidence of dimerization (34, 37). Equilibrium constants for monocyte chemoattractant protein-1 and -2 are in the µM region (34, 37), and a variety of studies have shown that the functionally active species for macrophage inflammatory protein-1alpha is a monomer (38).

Our data do not rule out the possibility that dimerization of the native chemokine may occur during or after initial binding of a monomer to the receptor. This is not possible for the monomeric chemokines discussed here, since the same mechanisms that prevent dimerization in solution will prevent dimerization on the receptor. However, there is no reason to believe that dimerization of the ligand is necessary for G-protein-coupled seven-transmembrane receptors. Most of the ligands for this family of receptors tend to be small molecular weight compounds such as formylmethionylleucylphenylalanine and epinephrine. For the growth factor type receptors, which have a distinctly different topology, dimerization of the receptor, and not the ligand, has been shown to be essential (39). All of the data presented here are from in vitro studies, and it is possible that these proteins may dimerize in vivo due to local high concentrations in the microenvironment at the receptor binding site. The dimerization may regulate the active concentration available for receptor binding or may stabilize the protein from proteolytic cleavage. A number of in vivo and in vitro studies seem to indicate that heparin binding on the cell surface is critical to generate a concentration gradient for leukocyte attraction and, hence, receptor binding (40-43). Preliminary studies from our laboratory suggest that the interaction of monomeric and native dimeric IL-8 with heparin is highly differential.3 Presently, all of the available data from our study and other studies indicate that chemokines have a tendency to associate at high concentrations but that the monomeric unit is sufficient to bind the receptor for functional activation.


FOOTNOTES

*   This work was supported by grants from the Protein Engineering Network of Centers of Excellence (to B. D. S., I. C. L., and C. M. K.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: Krishna Rajarathnam, PENCE, 713 Heritage Bldg., University of Alberta, Edmonton, Alberta T6G 2S2, Canada. Tel.: 403-492-7540; Fax: 403-492-1473; E-mail: kkr{at}rigel.biochem.ualberta.ca.
1    The abbreviations used are: IL-8, interleukin-8; MGSA, melanoma growth-stimulatory activity; NAP-2, neutrophil-activating peptide-2; RANTES, regulated upon activation, normal T-cell expressed, and presumably secreted.
2    The numbering corresponds to the sequence in IL-8. The corresponding positions are 2, 3 and 4 in NAP-2 and 6, 7 and 8 in MGSA.
3    K. Rajarathnam, C. M. Kay, I. Clark-Lewis, and B. D. Sykes, unpublished results.

REFERENCES

  1. Miller, M. D., and Krangel, M. S. (1992) Crit. Rev. Immunol. 12, 17-46 [Medline] [Order article via Infotrieve]
  2. Baggiolini, M., Dewald, B., and Moser, B. (1994) Adv. Immunol. 55, 97-179 [Medline] [Order article via Infotrieve]
  3. Furie, M. B., and Randolph, G. J. (1995) Am. J. Pathol. 146, 1287-1301 [Abstract]
  4. Clore, G. M., Appella, E., Yamada, M., Matsushima, K., and Gronenborn, A. M. (1990) Biochemistry 29, 1689-1696 [Medline] [Order article via Infotrieve]
  5. Baldwin, E. T., Weber, I. T., Charles, R., Xuan, J.-C., Appella, E., Yamada, M., Matsushima, K., Edwards, B. F. P., Clore, G. M., Gronenborn, A. M., and Wlodawer, A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 502-506 [Abstract]
  6. Kim, K.-S., Clark-Lewis, I., and Sykes, B. D. (1994) J. Biol. Chem. 269, 32909-32915 [Abstract/Free Full Text]
  7. Fairbrother, W. J., Reilly, D., Colby, T. J., Hesselgesser, J., and Horuk, R. (1994) J. Mol. Biol. 242, 252-270 [CrossRef][Medline] [Order article via Infotrieve]
  8. Malkowski, M. G., Wu, J. Y., Lazar, J. B., Johnson, P. H., and Edwards, B. F. P. (1995) J. Biol. Chem. 270, 7077-7087 [Abstract/Free Full Text]
  9. Rajarathnam, K., Sykes, B. D., Kay, C. M., Dewald, B., Geiser, T., Baggiolini, M., and Clark-Lewis, I. (1994) Science 264, 90-92 [Medline] [Order article via Infotrieve]
  10. Rajarathnam, K, Clark-Lewis, I., and Sykes, B. D. (1995) Biochemistry 34, 12983-12990 [Medline] [Order article via Infotrieve]
  11. Gayle, R. B., III, Sleath, P. R., Srinivason, S., Birks, C. W., Weerawarna, K. S., Cerretti, D. P., Kozlosky, C. J., Nelson, N., Bos, T. V., and Beckmann, M. P. (1993) J. Biol. Chem. 268, 7283-7289 [Abstract/Free Full Text]
  12. LaRosa, G. J., Thomas, K. M., Kaufmann, M. E., Mark, R., White, M., Taylor, L., Gray, G., Witt, D., and Navarro, J. (1992) J. Biol. Chem. 267, 25402-25406 [Abstract/Free Full Text]
  13. Schumacher, C., Clark-Lewis, I., Baggiolini, M., and Moser, B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10542-10546 [Abstract]
  14. Hesselgesser, J., Chitnis, C. E., Miller, L. H., Yansura, D. G., Simmons, L. C., Fairbrother, W. J., Kotts, C., Wirth, C., Gillece-Castro, B. L., and Horuk, R. (1995) J. Biol. Chem. 270, 11472-11476 [Abstract/Free Full Text]
  15. Yan, Z., Zhang, J., Holt, J. C., Stewart, G. J., Niewiarowski, S., and Poncz, M. (1994) Blood 84, 2329-2339 [Abstract/Free Full Text]
  16. Clark-Lewis, I., Schumacher, C., Baggiolini, M., and Moser, B. (1991) J. Biol. Chem. 266, 23128-23134 [Abstract/Free Full Text]
  17. Hébert, C. A., Vitangcol, R. V., and Baker, J. B. (1991) J. Biol. Chem. 266, 18989-18994 [Abstract/Free Full Text]
  18. Schraufstätter, I. U., Ma, M., Oades, Z. G., Barritt, D. S., and Cochrane, C. G. (1995) J. Biol. Chem. 270, 10428-10431 [Abstract/Free Full Text]
  19. Clark-Lewis, I., Dewald, B., Loetscher, M., Moser, B., and Baggiolini, M. (1994) J. Biol. Chem. 269, 16075-16081 [Abstract/Free Full Text]
  20. Clark-Lewis, I., Moser, B., Walz, A., Baggiolini, M., Scott, G. J., and Aebersold, R. (1991) Biochemistry 30, 3128-3135 [Medline] [Order article via Infotrieve]
  21. Peveri, P., Walz, A., Dewald, B., and Baggiolini, M. (1988) J. Exp. Med. 167, 1547-1559 [Abstract]
  22. Loetscher, P., Seitz, M., Clark-Lewis, I., Baggiolini, M., and Moser, B. (1994) FEBS Lett. 341, 187-192 [CrossRef][Medline] [Order article via Infotrieve]
  23. Creighton, T. E. (1992) Proteins: Structure and Molecular Properties, p. 141, W. H. Freeman and Company, New York
  24. Babul, J., and Stellwagen, E. (1969) Anal. Biochem. 28, 216-221 [Medline] [Order article via Infotrieve]
  25. Johnson, M. L., Correia, J. J., Yphantis, D. A., and Halvorson, H. R. (1981) Biophys. J. 36, 575-588 [Abstract]
  26. Yang, Y., Mayo, K. H., Daly, T. J., Barry, J. K., and La Rosa, G. J. (1994) J. Biol. Chem. 269, 20110-20118 [Abstract/Free Full Text]
  27. Schnitzel, W., Monschein, U., and Besemer, J. (1994) J. Leukocyte Biol. 55, 763-770 [Abstract]
  28. Lodi, P. J., Garrett, D. S., Kuszswski, J., Tsang, M. L.-S., Weatherbee, J. A., Leonard, W. J., Gronenborn, A. M., and Clore, G. M. (1994) Science 263, 1762-1766 [Medline] [Order article via Infotrieve]
  29. Skelton, N. J., Aspiras, F., Ogez, J., and Schall, T. J. (1995) Biochemistry 34, 5329-5342 [Medline] [Order article via Infotrieve]
  30. Chung, C.-W., Cooke, R. M., Proudfoot, A. E. I., and Wells, T. N. C. (1995) Biochemistry 34, 9307-9314 [Medline] [Order article via Infotrieve]
  31. St. Charles, R., Walz, D. A., and Edwards, B. F. P. (1989) J. Biol. Chem. 264, 2092-2099 [Abstract/Free Full Text]
  32. Zhang, X., Chen, L., Bancroft, D. P., Lai, C. K., and Maione, T. E. (1994) Biochemistry 33, 8361-8366 [Medline] [Order article via Infotrieve]
  33. Burrows, S. D., Doyle, M. L., Murphy, K. P., Franklin, S. G., White, J. R., Brooks, I., McNulty, D. E., Scott, M. O., Knutson, J. R., Porter, D., Young, P. R., and Hensley, P. (1994) Biochemistry 33, 12741-12745 [Medline] [Order article via Infotrieve]
  34. Paolini, J. F., Willard, D., Consler, T., Luther, M., and Krangel, M. S. (1994) J. Immunol. 153, 2704-2717 [Abstract/Free Full Text]
  35. Ida, N., Sakurai, S., Hosoi, K., and Kunitomo, T. (1992) J. Immunol. Methods 156, 27-38 [CrossRef][Medline] [Order article via Infotrieve]
  36. Gross, V., Andreesen, R., Leser, H. G., Ceska, M., Liehl, E., Lausen, M., Farthmann, E. H., and Scholmerich, J. (1992) Eur. J. Clin. Invest. 22, 200-203 [Medline] [Order article via Infotrieve]
  37. Clark-Lewis, I., Kim, K-S., Rajarathnam, K., Gong, J.-H., Dewald, B., Moser, B., Baggiolini, M., and Sykes, B. D. (1995) J. Leukocyte Biol. 57, 703-711 [Abstract]
  38. Patel, S. R., Evans, S., Dunne, K., Knight, G. C., Morgan, P. J., Varley, P. G., and Craig, S. (1993) Biochemistry 32, 5466-5471 [Medline] [Order article via Infotrieve]
  39. deVos, A. M., Ultsch, M., and Kossiakoff, A. A. (1992) Science 255, 306-312 [Medline] [Order article via Infotrieve]
  40. Rot, A. (1992) Cytokine 4, 346-352
  41. Rot, A. (1992) Immunol. Today 13, 291-293 [CrossRef][Medline] [Order article via Infotrieve]
  42. Tanaka, Y., Adams, D. H., Hubscher, S., Hirano, H., Siebenlist, U., and Shaw, S. (1993) Nature 254, 79-82
  43. Webb, L. M. C., Ehrengruber, M. U., Clark-Lewis, I., Baggiolini, M., and Rot, A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7158-7172 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.